Chonluten 20mg
You’re now subscribed to price tracking for this product. We’ll notify you if the price drops.
Fast Delivery
Quick, reliable shipping to any location.
Free & easy returns
Return this item by mail or in store within 90 days for a full refund.
About Chonluten 20mg
Chonluten is a tripeptide (Glu-Asp-Leu) from the Khavinson bioregulatory series targeting bronchial and pulmonary tissue — the same tissue target as Bronchogen, but a different sequence. That’s not a coincidence. In the Khavinson framework, different peptide sequences targeting the same organ are proposed to interact with different gene promoter sites, producing distinct regulatory profiles within the same tissue. So Chonluten (Glu-Asp-Leu) and Bronchogen (Ala-Glu-Asp) are complementary tools for the same research tissue, not duplicates.
The distinction between Chonluten and Bronchogen is sequence-dependent, and what downstream differences this produces in pulmonary models is one of the specific comparative questions within the Khavinson series. Published Khavinson research on Chonluten examines lung epithelial cell homeostasis, bronchial mucosa gene expression, and age-related changes in respiratory tissue biology. As with the broader series, most literature originates from the Saint Petersburg Institute of Bioregulation and Gerontology.
Specifications
| Sequence | Glu-Asp-Leu |
|---|---|
| Molecular Weight | ~350 Da (tripeptide) |
| Purity | ≥98% (supplier batch spec; 99.4% avg across independently tested lots) |
| Form | Lyophilized powder |
| Sizes | 20mg |
Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.
Quality: Every product ships to a ≥98% supplier batch specification; selected lots are independently tested by Janoshik Analytical (HPLC purity analysis and mass spectrometry identity confirmation; 99.4% average purity across published reports), searchable by batch code at certapeptides.com/verify. EU-based QC under CERTALAB S.R.L.
Frequently Asked Questions
If Chonluten and Bronchogen both target lung tissue, which one to use?
The choice depends on what you’re studying. In the Khavinson framework, the different sequences (Glu-Asp-Leu versus Ala-Glu-Asp) are proposed to interact with different promoter sites in lung tissue, modulating distinct gene programs. If you want to compare the two sequences in the same model, study both. If you have specific endpoint data from published Khavinson research pointing to one compound for a particular marker, use that one. If you have no prior data to guide selection, Bronchogen has slightly more published literature.
What are the primary research endpoints for pulmonary Khavinson peptides?
Age-related bronchial epithelial decline, respiratory tissue homeostasis, and mucosa gene expression markers are the primary applications. Both Bronchogen and Chonluten have been studied in aging models examining changes in lung-specific protein synthesis and tissue morphology. The data set is largely from the Khavinson Institute, with some English-language publications in gerontology journals.
For research purposes only. Not for human consuption
Reviews
There are no reviews yet.